Sugi Predict

Sugi Predict / Compounds / SCHEMBL29655934

SCHEMBL29655934

SCHEMBL29655934

NC(=O)Nc1cccnc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.65
▸ NPC1 O15118 2/20 0.65
▸ PKM P14618 1/20 0.65
▸ LMNA P02545 2/20 0.62
▸ HIF1A Q16665 1/20 0.62
▸ NAMPT P43490 3/20 0.61
▸ TP53 P04637 1/20 0.59
▸ MEN1 O00255 4/20 0.57
▸ KMT2A Q03164 4/20 0.57
▸ ALDH1A1 P00352 3/20 0.57
▸ KDM4E B2RXH2 2/20 0.57
▸ PRKCI P41743 1/20 0.57
▸ CYP11B1 P15538 3/20 0.56
▸ CYP11B2 P19099 3/20 0.56
▸ CDK2 P24941 1/20 0.56
▸ FLT4 P35916 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ HTT P42858 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162008 1.00 RAB9A (0.65) RAB9ANPC1PKMLMNAHIF1A
Hydrochloric Acid SCHEMBL27677130 0.98 RAB9A (0.62) RAB9ANPC1PKMLMNAHIF1A
Boric Acid SCHEMBL29121086 0.94 RAB9A (0.59) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL6989004 0.85 RAB9A (0.71) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL28052644 0.84 ATG4B (0.61) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL30504811 0.83 RAB9A (0.89) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL9637653 0.83 MEN1 (0.77) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL30051982 0.83 MEN1 (0.77) RAB9ANPC1PKMLMNAHIF1A
Hydrochloric Acid SCHEMBL28051146 0.83 RAB9A (0.69) RAB9ANPC1PKMLMNAHIF1A
SCHEMBL6062650 0.82 RAB9A (0.67) RAB9ANPC1PKMLMNAHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023176554-A1 COGNITIVE-FUNCTION-IMPROVING AGENT 国立大学法人東北大学 2023-09-21 — — WO claimed
CN-111526877-B Compounds and compositions for IRE1 inhibition 奥普提卡拉公司 2023-08-25 — — CN claimed
WO-2023088285-A1 SMALL MOLECULE INHIBITOR AGAINST NASOPHARYNGEAL CARCINOMA, PREPARATION METHOD FOR COMPOUND AND APPLICATION THEREOF 深圳湾实验室 2023-05-25 — — WO claimed
CN-115109049-A Triazine compound containing aryl urea structure and application thereof 江西科技师范大学 2022-09-27 — — CN claimed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US disclosed
CN-112979615-B Quinazoline urea compound, preparation method thereof, preparation intermediate, pharmaceutical composition and application 上海医药集团股份有限公司 2024-08-09 — — CN disclosed
US-20240262801-A1 COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES MONDEGO BIO, LDA. (PT) 2024-08-08 — — US disclosed
US-11999694-B2 Delivery of therapeutic alkaloid compounds SENSORIUM THERAPEUTICS, INC. (US) 2024-06-04 — — US disclosed
CN-112300172-B Bruton tyrosine kinase inhibitors 比奥根MA公司 2024-01-16 — — CN disclosed
CN-112105355-B ABHD12 inhibitors and methods of making and using the same 斯克利普斯研究所 2024-01-02 — — CN disclosed
WO-2023176554-A1 COGNITIVE-FUNCTION-IMPROVING AGENT 国立大学法人東北大学 2023-09-21 — — WO disclosed
CN-111526877-B Compounds and compositions for IRE1 inhibition 奥普提卡拉公司 2023-08-25 — — CN disclosed
CN-115109049-B Triazine compound containing aryl urea structure and application thereof 江西科技师范大学 2023-08-15 — — CN disclosed
WO-2023088285-A1 SMALL MOLECULE INHIBITOR AGAINST NASOPHARYNGEAL CARCINOMA, PREPARATION METHOD FOR COMPOUND AND APPLICATION THEREOF 深圳湾实验室 2023-05-25 — — WO disclosed
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2023-05-25 — — US disclosed
CN-115279770-A Compounds and compositions for treating diseases associated with STING activity 艾福姆德尤股份有限公司 2022-11-01 — — CN disclosed
CN-115109049-A Triazine compound containing aryl urea structure and application thereof 江西科技师范大学 2022-09-27 — — CN disclosed
US-20220213074-A1 ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2022-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB RAB9A 2770/4885NPC1 1965/4885PKM 778/4885
US-20240262801-A1 COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES PPM1A, TH, PPM1G RAB9A 2110/4885NPC1 2925/4885PKM 1099/4885
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS PNMT, HNMT, NNMT RAB9A 571/4885NPC1 296/4885PKM 1751/4885
US-20220213074-A1 ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME ABHD12, SAMHD1, ABHD11 RAB9A 2788/4885NPC1 1734/4885PKM 4205/4885
US-11999694-B2 Delivery of therapeutic alkaloid compounds PNMT, HNMT, NNMT RAB9A 571/4885NPC1 296/4885PKM 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.